Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15080504 | 0.75 | MEN1 (0.50) | ADRB2ADRB1ADRB3KCNH2MEN1 | |
| SCHEMBL12800176 | 0.73 | ADRB2 (0.39) | ADRB2ADRB1ADRB3KCNH2MEN1 | |
| SCHEMBL44477 | 0.73 | NOS1 (0.51) | KCNH2NOS2NOS1 | |
| SCHEMBL10603769 | 0.73 | KCNH2 (0.46) | ADRB2ADRB1ADRB3KCNH2NOS2 | |
| SCHEMBL14643881 | 0.71 | NOS1 (0.50) | KCNH2NOS1 | |
| SCHEMBL3828155 | 0.71 | NOS1 (0.50) | KCNH2NOS1 | |
| SCHEMBL11588307 | 0.71 | NOS1 (0.50) | KCNH2NOS1 | |
| SCHEMBL9729165 | 0.71 | NOS1 (0.50) | KCNH2NOS1 | |
| Ammonia Solution, Strong SCHEMBL28007740 | 0.71 | NOS1 (0.50) | KCNH2NOS1 | |
| SCHEMBL13947093 | 0.71 | MEN1 (0.53) | ADRB2ADRB1ADRB3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004279-A1 | Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases | AB SCIENCE (FR) | 2008-01-03 | — | — | US | claimed |
| US-20070249628-A1 | Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons | MOUSSY ALAIN | 2007-10-25 | — | — | US | claimed |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | AB SCIENCE | 2007-09-27 | — | — | US | claimed |
| US-20070191267-A1 | Use of tyrosine kinase inhibitors for treating cerebral ischemia | AB SCIENCE | 2007-08-16 | — | — | US | claimed |
| EP-1758654-A1 | USE OF C-KIT INHIBITORS FOR TREATING PLASMODIUM RELATED DISEASES | AB Science (FR) | 2007-03-07 | — | — | EP | claimed |
| EP-1755592-A1 | USE OF C-KIT INHIBITORS FOR TREATING INFLAMMATORY MUSCLE DISORDERS INCLUDING MYOSITIS AND MUSCULAR DYSTROPHY | AB Science (FR) | 2007-02-28 | — | — | EP | claimed |
| US-20070032521-A1 | Use of c-kit inhibitors for treating type II diabetes | AB SCIENCE | 2007-02-08 | — | — | US | claimed |
| EP-1746990-A1 | USE OF MAST CELLS INHIBITORS FOR TREATING PATIENTS EXPOSED TO CHEMICAL OR BIOLOGICAL WEAPONS | AB Science (FR) | 2007-01-31 | — | — | EP | claimed |
| EP-1742633-A2 | USE OF C-KIT INHIBITORS FOR TREATING FIBROSIS | AB Science (FR) | 2007-01-17 | — | — | EP | claimed |
| EP-1653934-A2 | USE OF C-KIT INHIBITORS FOR TREATING TYPE II DIABETES | AB Science (FR) | 2006-05-10 | — | — | EP | claimed |
| WO-2005115304-A2 | USE OF C-KIT INHIBITORS FOR TREATING FIBRODYSPLASIA | AB SCIENCE (FR) | 2005-12-08 | — | — | WO | claimed |
| WO-2005112920-A1 | USE OF MAST CELLS INHIBITORS FOR TREATING PATIENTS EXPOSED TO CHEMICAL OR BIOLOGICAL WEAPONS | AB SCIENCE (FR) | 2005-12-01 | — | — | WO | claimed |
| WO-2005102455-A1 | USE OF C-KIT INHIBITORS FOR TREATING PLASMODIUM RELATED DISEASES | AB SCIENCE (FR) | 2005-11-03 | — | — | WO | claimed |
| WO-2005102318-A1 | USE OF C-KIT INHIBITORS FOR TREATING HIV RELATED DISEASES | AB SCIENCE (FR) | 2005-11-03 | — | — | WO | claimed |
| WO-2005102325-A1 | USE OF C-KIT INHIBITORS FOR TREATING INFLAMMATORY MUSCLE DISORDERS INCLUDING MYOSITIS AND MUSCULAR DYSTROPHY | AB SCIENCE (FR) | 2005-11-03 | — | — | WO | claimed |
| WO-2005102326-A2 | USE OF C-KIT INHIBITORS FOR TREATING RENAL DISEASES | AB SCIENCE (FR) | 2005-11-03 | — | — | WO | claimed |
| WO-2005102346-A2 | USE OF C-KIT INHIBITORS FOR TREATING FIBROSIS | AB SCIENCE (FR) | 2005-11-03 | — | — | WO | claimed |
| WO-2005016323-A2 | USE OF C-KIT INHIBITORS FOR TREATING TYPE II DIABETES | AB SCIENCE (FR) | 2005-02-24 | — | — | WO | claimed |
| WO-2004098612-A2 | CALCITRIOL ANALOGS OF USES THEREOF | AB SCIENCE (FR) | 2004-11-18 | — | — | WO | claimed |
| WO-2004096225-A2 | USE OF TYROSINE KINASE INHIBITORS FOR TREATING CEREBRAL ISCHEMIA | AB SCIENCE (FR) | 2004-11-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | KIT, CPA3, CMA1 | ADRB2 2444/4885ADRB1 1864/4885ADRB3 556/4885 |
| US-20080004279-A1 | Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases | KIT, JAK3, MAP3K3 | ADRB2 4215/4885ADRB1 3857/4885ADRB3 1751/4885 |
| US-20070249628-A1 | Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons | KIT, CPA3, CMA1 | ADRB2 3174/4885ADRB1 2904/4885ADRB3 704/4885 |
| US-20070032521-A1 | Use of c-kit inhibitors for treating type II diabetes | KIT, CPA3, CMA1 | ADRB2 1235/4885ADRB1 1603/4885ADRB3 1446/4885 |
| US-20070191267-A1 | Use of tyrosine kinase inhibitors for treating cerebral ischemia | KIT, MAST3, CPA3 | ADRB2 2702/4885ADRB1 2806/4885ADRB3 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.